Title: Cytarabine dose for acute myeloid leukemia
Authors: Löwenberg, Bob ×
Pabst, Thomas
Vellenga, Edo
van Putten, Wim
Schouten, Harry C
Graux, Carlos
Ferrant, Augustin
Sonneveld, Pieter
Biemond, Bart J
Gratwohl, Alois
de Greef, Georgine E
Verdonck, Leo F
Schaafsma, Martijn R
Gregor, Michael
Theobald, Matthias
Schanz, Urs
Maertens, Johan
Ossenkoppele, Gert J
Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group #
Issue Date: Mar-2011
Series Title: New England Journal of Medicine vol:364 issue:11 pages:1027-1036
Abstract: Cytarabine (ara-C) is an important drug in the treatment of acute myeloid leukemia (AML). High-dose cytarabine (2000 to 3000 mg per square meter of body-surface area) is toxic but results in higher rates of relapse-free survival than does the conventional dose of 100 to 400 mg per square meter. Intermediate dose levels have not been thoroughly evaluated.
ISSN: 0028-4793
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Hematology Section (-)
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science